STOCK TITAN
  1. Home
  2. Sec-filings
  3. SNTI
  4. [Form 4] Senti Biosciences, Inc. Insider Trading Activity

[Form 4] Senti Biosciences, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Form 4 Overview: On 06/27/2025 Senti Biosciences (ticker: SNTI) filed a Form 4 disclosing a routine equity award to board member Brenda Cooperstone. The report covers a single transaction dated 06/25/2025 and was signed by Timothy Lu as attorney-in-fact.

Key Transaction Details: The filing records the grant of 21,950 non-qualified stock options (Code A – grant) with an exercise price of $2.05 per share and an expiration date of 06/24/2035. Following the grant, Cooperstone beneficially owns exactly 21,950 derivative securities; no common shares or other derivative movements were reported in Table I.

Vesting Schedule: According to the footnote, 100% of the options vest on the earlier of (i) the first anniversary of the grant or (ii) the company’s 2026 Annual Meeting, contingent on the director’s continued service. Thus, full vesting is expected by mid-2026 at the latest.

Investor Implications: The event is part of standard director compensation and does not involve any open-market purchase or sale of existing shares. At 21,950 shares, the potential dilution is de-minimis relative to Senti’s total shares outstanding, and the strike price sits close to recent market levels, aligning incentives without materially affecting near-term cash flow or share count. No earnings, revenue data, or other operational disclosures accompany the filing.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Routine director option grant—21,950 options at $2.05; no shares sold, minimal dilution, neutral impact.

The Form 4 details a standard equity incentive for director Brenda Cooperstone. The award size is modest in the context of SNTI’s float and carries a 10-year term with one-year vesting. Because no common shares changed hands and the transaction adds only a small contingent share count, the filing has no immediate earnings or cash-flow consequences. Investors may view the grant as positive governance alignment, but it does not signal directional insight into fundamentals. Overall, the disclosure is routine and non-material for valuation models.

Insider COOPERSTONE BRENDA
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 21,950 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 21,950 shares (Direct)
Footnotes (1)
  1. [object Object]
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
COOPERSTONE BRENDA
(Last) (First) (Middle)
C/O SENTI BIOSCIENCES, INC.
2 CORPORATE DRIVE FIRST FLOOR
(Street)
SOUTH SAN FRANCISCO CA 94080
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Senti Biosciences, Inc. [ SNTI ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $2.05 06/25/2025 A 21,950 (1) 06/24/2035 Common Stock 21,950 $0 21,950 D
Explanation of Responses:
1. 100% of the shares underlying this option vest upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the 2026 Annual Meeting, subject to the reporting person's continued service through the applicable vesting date.
/s/ Timothy Lu, attorney-in-fact 06/27/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did SNTI director Brenda Cooperstone report in the latest Form 4?

A grant of 21,950 stock options with a $2.05 exercise price and no share sales.

At what price can the options granted to Brenda Cooperstone be exercised?

The exercise price is $2.05 per share.

When will Brenda Cooperstone's options vest and expire?

They vest 100% by the earlier of 06/25/2026 or the 2026 AGM and expire on 06/24/2035.

How many derivative securities does the director own after this transaction?

She beneficially owns 21,950 stock options following the grant.

Did the Form 4 disclose any sales of SNTI common stock?

No; the filing only reported an option grant with no dispositions.